4.75
Precedente Chiudi:
$4.98
Aprire:
$5
Volume 24 ore:
59,958
Relative Volume:
0.49
Capitalizzazione di mercato:
$15.16M
Reddito:
-
Utile/perdita netta:
$-37.75M
Rapporto P/E:
-1.4615
EPS:
-3.25
Flusso di cassa netto:
$-30.91M
1 W Prestazione:
-0.42%
1M Prestazione:
-7.41%
6M Prestazione:
+1,577%
1 anno Prestazione:
+128.37%
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Confronta CLRB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CLRB
Cellectar Biosciences Inc
|
4.75 | 15.86M | 0 | -37.75M | -30.91M | -3.25 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-05 | Ripresa | Ladenburg Thalmann | Buy |
2020-07-01 | Iniziato | Oppenheimer | Outperform |
2020-01-21 | Ripresa | ROTH Capital | Buy |
2019-09-13 | Iniziato | ROTH Capital | Buy |
2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
How to track smart money flows in Cellectar Biosciences Inc.2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Is Cellectar Biosciences Inc. forming a bottoming baseWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
What drives Cellectar Biosciences Inc stock priceStock Valuation Metrics & Low Cost Wealth Investment - earlytimes.in
How analysts rate Cellectar Biosciences Inc. stock todayBond Market & Real-Time Market Sentiment Alerts - newser.com
Will Cellectar Biosciences Inc. stock pay special dividendsTrade Analysis Summary & Safe Capital Growth Trade Ideas - newser.com
Is Cellectar Biosciences Inc. stock a safe investment in uncertain markets2025 Key Highlights & Community Verified Swing Trade Signals - newser.com
Cellectar’s experimental cancer drug shows promise in pancreatic models By Investing.com - Investing.com Nigeria
Cellectar Biosciences Inc. stock prediction for this week2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Cellectar (CLRB) Unveils Promising Preclinical Results for CLR 2 - GuruFocus
Cellectar’s experimental cancer drug shows promise in pancreatic models - Investing.com India
Cellectar Biosciences Presented Promising Preclinical Data - GlobeNewswire
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - Stock Titan
What technical models suggest about Cellectar Biosciences Inc.’s comebackWeekly Profit Summary & Daily Risk Controlled Trade Plans - newser.com
Can Cellectar Biosciences Inc. rally from current levels2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Is Cellectar Biosciences Inc. stock a bargain at current levelsIndex Update & AI Driven Stock Movement Reports - newser.com
Is Cellectar Biosciences Inc. stock a buy in volatile markets2025 Major Catalysts & Fast Gain Stock Tips - newser.com
Using Python tools to backtest Cellectar Biosciences Inc. strategiesIPO Watch & Long-Term Investment Growth Plans - newser.com
Predicting Cellectar Biosciences Inc. trend using moving averagesSell Signal & Daily Growth Stock Investment Tips - newser.com
Is Cellectar Biosciences Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Cellectar Biosciences Raises $5.8M Through Warrant Exercise - MSN
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants - Investing.com Canada
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants By Investing.com - Investing.com South Africa
Will Cellectar Biosciences Inc. price bounce be sustainable2025 Top Decliners & Daily Profit Focused Screening - newser.com
Understanding Cellectar Biosciences Inc.’s price movementWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Custom watchlist performance reports with Cellectar Biosciences Inc.CPI Data & Long-Term Growth Plans - newser.com
Analyzing net buyer seller activity in Cellectar Biosciences Inc.Quarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences (CLRB) Secures $5.8 Million Through Warran - GuruFocus
Cellectar Biosciences raises $5.8 million through warrant exercise - Investing.com
Cellectar Biosciences enters agreements to raise $5.8M - TipRanks
Cellectar Biosciences raises $5.8 million through warrant exercise By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. enters into agreements to raise $5.8 million - MarketScreener
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - GlobeNewswire
Cellectar’s cancer drug advances toward European approval By Investing.com - Investing.com Nigeria
Cellectar Biosciences Announces European Medicines Agency - GlobeNewswire
Cellectar Biosciences (CLRB) Receives Positive Feedback for EU M - GuruFocus
What margin trends mean for Cellectar Biosciences Inc. stockEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com
Cellectar’s cancer drug advances toward European approval - Investing.com
Cellectar Biosciences Stock Rises Over EMA's Advise On CMA Filing For Iopofosine I 131 - Nasdaq
Cellectar Biosciences (CLRB) Moves Toward European Market with P - GuruFocus
Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer - MarketScreener
Cellectar Biosciences Plans Conditional Marketing Authorization Submission for Iopofosine I 131 as Treatment for Refractory Waldenstrom Macroglobulinemia in Europe by Early 2026 - Quiver Quantitative
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cellectar Biosciences Inc Azioni (CLRB) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):